Overexpression of the cancer stem cell marker CD117 predicts poor prognosis in epithelial ovarian cancer patients: evidence from meta-analysis
Authors Yang B, Yan X, Liu L, Jiang C, Hou S
Received 9 March 2017
Accepted for publication 25 April 2017
Published 13 June 2017 Volume 2017:10 Pages 2951—2961
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr XuYu Yang
Bikang Yang,1,* Xuebing Yan,2,* Liguo Liu,3,* Chunyu Jiang,4 Shuping Hou1
1Department of Gynecology and Obstetrics, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 2Department of General Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University, 3Department of General Surgery, 4Deparment of Radiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Purpose: Cancer stem cells have recently been identified as a key driving factor for tumor metastasis and chemoresistance. CD117 is a well-established cancer stem cell marker, but its clinical significance in epithelial ovarian cancer (EOC) remains controversial. Therefore, we aimed to identify correlations between CD117 expression and clinical features and outcomes in EOC patients in this meta-analysis.
Materials and methods: A literature search was performed in the PubMed, Cochrane Library, Web of Science, EMBASE, and OVID databases to identify eligible studies. Correlations between CD117 expression and clinicopathological parameters and overall survival or disease-free survival were analyzed. A subgroup analysis was then performed, which was classified by patient ethnicity and age at diagnosis, study sample size, and tumor histological type.
Results: A total of seven studies enrolling 1,247 EOC patients were included in this meta-analysis. Our results demonstrated that CD117 expression was significantly correlated with age (pooled odds ratio [OR] =1.67, 95% confidence interval [CI] =1.05–2.66), International Federation of Gynecology and Obstetrics stage (pooled OR =1.99, 95% CI =1.31–3.02), tumor differentiation grade (pooled OR =2.46, 95% CI =1.48–4.10), and histological type (pooled OR =1.85, 95% CI =1.05–3.26). EOC patients with high CD117 expression had significantly worse OS (hazard ratio [HR] =1.39, 95% CI =1.03–1.90) than patients with low CD117 expression. However, no significant correlation was found between CD117 expression and disease-free survival (HR =1.31, 95% CI =0.79–2.17). In subgroup analysis, CD117 was identified as a significant prognostic factor for overall survival in European patients (HR =1.59, 95% CI =1.13–2.23), younger patients (<60 years) (HR =1.59, 95% CI =1.10–2.30), studies with sample sizes >200 (HR =1.84, 95% CI =1.32–2.56), and the mixed histological types (HR =1.47; 95% CI =1.08–2.00).
Conclusion: Our meta-analysis suggests that CD117 is associated with EOC progression and can serve as a promising prognostic predictor for EOC patients. However, larger scale multicenter clinical trials are still needed to further validate our results.
Keywords: epithelial ovarian cancer, CD117, cancer stem cell, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]